US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30-expressing mycosis fungoides
pharmabiz | November 11, 2017
Seattle Genetics has announced that the US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common subtypes of cutaneous T-cell lymphoma (CTCL).